Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Allogene Therapeutics Q4 2023 GAAP EPS $(0.51) Misses $(0.46) Estimate, Sales $21.000K Miss $23.571K Estimate

Author: Benzinga Newsdesk | March 14, 2024 04:17pm
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.46) by 10.87 percent. This is a 23.88 percent increase over losses of $(0.67) per share from the same period last year. The company reported quarterly sales of $21.000 thousand which missed the analyst consensus estimate of $23.571 thousand by 10.91 percent. This is a 19.23 percent decrease over sales of $26.000 thousand the same period last year.

Posted In: ALLO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist